AUC from day 0 to 140 (AUC 140) of 25(OH)D was 40% (D3 daily) to 55% (D3 2-weekly) higher with active-treatment than placebo ( p < 0.001). Baseline 25(OH)D level was 39.8(11.9) and increased by 3.3(11.6) and 28.6(16.3) nmol/L, in the placebo and active-treatment groups, respectively. Mean(SD) age was 33.0(8.5) year, 41% were males, and 85% completed follow-up. Primary endpoint was area-under-the-curve (AUC) of 25(OH)D (25(OH)D2 + 25(OH)D3) adjusted for sex, BMI, and baseline 25(OH)D level. The results of 269 participants were available for analysis. D2, D3, 25(OH)D2, and 25(OH)D3 Serum levels were determined blindly on days 0,1,2,3,4,7,14, and 2-weekly thereafter by high performance liquid chromatography assay. Randomization sequence, stratified by body-mass-index (BMI) and sex, was concealed from study coordinators and participants who were then blinded to capsules’ content. We randomized 279 adults to daily D2, D3, D2/D3, or placebo 2-weekly D2 or D3 or 4-weekly D2 or D3 (250,000 IU over/140 days).
Controversy continues on ergocalciferol (D2) and cholecalciferol (D3) relative potency as well as on dosing-schedule and sex role in raising 25-hydroxy D (25(OH)D) level, the best indicator of D status.
Vitamin D (D) supplements are indispensable for its world-wide deficiency.
0 kommentar(er)
